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Summary
Background Previous studies have independently validated the prognostic relevance of residual cancer burden (RCB) 
after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis 
to evaluate the relationship of RCB with long-term prognosis across different phenotypic subtypes of breast cancer, to 
assess generalisability in a broad range of practice settings.
Methods In this pooled analysis, 12 institutes and trials in Europe and the USA were identified by personal 
communications with site investigators. We obtained participant-level RCB results, and data on clinical and 
pathological stage, tumour subtype and grade, and treatment and follow-up in November, 2019, from patients (aged 
≥18 years) with primary stage I–III breast cancer treated with neoadjuvant chemotherapy followed by surgery. We 
assessed the association between the continuous RCB score and the primary study outcome, event-free survival, 
using mixed-effects Cox models with the incorporation of random RCB and cohort effects to account for between-
study heterogeneity, and stratification to account for differences in baseline hazard across cancer subtypes defined by 
hormone receptor status and HER2 status. The association was further evaluated within each breast cancer subtype 
in multivariable analyses incorporating random RCB and cohort effects and adjustments for age and pretreatment 
clinical T category, nodal status, and tumour grade. Kaplan-Meier estimates of event-free survival at 3, 5, and 10 years 
were computed for each RCB class within each subtype.
Findings We analysed participant-level data from 5161 patients treated with neoadjuvant chemotherapy 
between Sept 12, 1994, and Feb 11, 2019. Median age was 49 years (IQR 20–80). 1164 event-free survival events 
occurred during follow-up (median follow-up 56 months [IQR 0–186]). RCB score was prognostic within each breast 
cancer subtype, with higher RCB score significantly associated with worse event-free survival. The univariable 
hazard ratio (HR) associated with one unit increase in RCB ranged from 1·55 (95% CI 1·41–1·71) for hormone 
receptor-positive, HER2-negative patients to 2·16 (1·79–2·61) for the hormone receptor-negative, HER2-positive 
group (with or without HER2-targeted therapy; p<0·0001 for all subtypes). RCB score remained prognostic for event-
free survival in multivariable models adjusted for age, grade, T category, and nodal status at baseline: the adjusted 
HR ranged from 1·52 (1·36–1·69) in the hormone receptor-positive, HER2-negative group to 2·09 (1·73–2·53) in 
the hormone receptor-negative, HER2-positive group (p<0·0001 for all subtypes).
Interpretation RCB score and class were independently prognostic in all subtypes of breast cancer, and generalisable 
to multiple practice settings. Although variability in hormone receptor subtype definitions and treatment across 
patients are likely to affect prognostic performance, the association we observed between RCB and a patient’s residual 
risk suggests that prospective evaluation of RCB could be considered to become part of standard pathology reporting 
after neoadjuvant therapy.
Funding National Cancer Institute at the US National Institutes of Health.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
Neoadjuvant chemotherapy was introduced for patients 
with locally advanced inoperable breast cancer in the 
late 1970s.1 Neoadjuvant chemotherapy is at least as 
effective as adjuvant therapy and has several additional 
advantages.2 Compared with adjuvant therapy, neo­
adjuvant therapy permits less extensive breast and axillary 
surgery by downstaging the tumour and allows 
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monitoring of the treatment response, which provides 
important prognostic information. Pathological complete 
response (pCR) to neoadjuvant chemotherapy, defined as 
the absence of residual invasive disease in the breast and 
axilla, is strongly associated with improved long­term 
survival outcomes.3–5 The influential meta­analysis of 
the Collaborative Trials in Neoadjuvant Breast Cancer 
(CTNeoBC) showed that patients with pCR have improved 
event­free survival and overall survival, with the greatest 
prognostic value in patients with highly proliferative 
tumours.4 Consequently, the US Food and Drug 
Administration and European Medicines Agency issued 
initial guidance in 2012–14 for the use of pCR as a 
regulatory endpoint for accelerated approval of new drugs 
for neoadjuvant chemotherapy of breast cancer. Since 
these guidances were issued, contemporary trials have 
incorporated standardised pathological assess ments of 
surgical resection specimens and validated pCR as a 
reliable prognostic marker.6 Increasingly, the presence or 
absence of residual disease is being used to guide adjuvant 
decisions following neoadjuvant chemo therapy.7,8
The binary outcome of pCR versus residual disease 
confers little information, offering no distinction among 
patients with varied amounts of residual disease. 
Furthermore, methods to evaluate surgical specimens 
and report residual disease have not been adequately 
standardised within pathology practice. The residual 
cancer burden (RCB) method, first described in 2007, 
was designed to address these shortcomings by providing 
a standard set of methods to evaluate and quantify the 
extent of residual disease in breast and axillary lymph 
nodes following neoadjuvant chemotherapy.9 It yields a 
continuous score, with pCR being the equivalent of an 
RCB score of zero. Empirically derived cutpoints are 
applied to the continuous score to define four RCB 
classes, from RCB­0 to RCB­3, that represent an 
increasing residual disease burden. RCB assessments 
are highly reproducible between pathologists;10,11 and 
both RCB and its classes have been validated as 
prognostic in single­institution studies12–15 and 
multicentre trials.16–19 However, individually, these cohorts 
are too small to obtain accurate estimates of prognosis 
related to RCB within the various subtypes of breast 
cancer. Therefore, we performed a pooled participant­
level analysis of multiple clinical trials and cohorts to 
evaluate the overall association between RCB and long­
term outcomes, with emphasis on the breast cancer 
subtypes defined by hormone receptor and HER2 
receptor status. Our aim was to understand the 
prognostic value of RCB relative to pCR in the context of 
breast cancer subtypes, to optimise the interpretation of 
RCB and better inform patient management across a 
broad array of practice settings.
Methods
Study design and patient cohorts
In this pooled analysis, 12 institutes and trials in Europe 
and the USA were identified by personal communications 
Research in context
Evidence before this study
The seminal meta-analysis of the Collaborative Trials in 
Neoadjuvant Breast Cancer working group published in 2014 
showed that on an individual level, achieving a pathological 
complete response (pCR) following neoadjuvant chemotherapy 
was associated with improved long-term survival outcomes. 
On Sept 13, 2021, a search of the PubMed database using the 
term “pathological complete response and breast cancer 
prognosis” yielded 1531 published articles between Jan 1, 2014, 
and Dec 31, 2019. However, pCR does not provide distinction 
among patients with residual disease. The residual cancer 
burden (RCB) method was proposed in 2007 as a standardised 
methodological approach to evaluate and quantitate the extent 
of residual disease in breast and axillary lymph nodes following 
neoadjuvant chemotherapy. A further search of the PubMed 
database (Sept 13, 2021), using the term “residual cancer burden 
and breast cancer prognosis” identified 166 articles published 
between Jan 1, 2007, and Dec 31, 2019. Among these articles, 
single-institution studies and multicentre trials had validated 
RCB as a prognostic score in breast cancer.
Added value of this study
Individually, the cohorts in previous studies evaluating the 
prognostic value of RCB are too small to obtain accurate 
estimates within the various molecular subtypes of breast 
cancer. By assembling a pooled cohort of 5161 patients across 
12 participating groups from Europe and the USA representing 
a variety of clinical settings, our study was able to validate the 
prognostic value of RCB overall and within each hormone 
receptor and HER2 subtype, with regard to event-free survival 
and distant relapse-free survival. In addition, by evaluating RCB 
as a continuous measure in a model that allows for non-linear 
effect within each subtype, we were able to further characterise 
how risk of recurrence or death changes with increasing RCB 
and compare this relationship between different breast cancer 
subtypes.
Implications of all the available evidence
The prognostic importance of pCR (equivalent to RCB score 0) 
is well established. RCB score adds substantially to the binary 
assessment of pCR versus residual disease in predicting long-
term survival. The observed prognostic consistency of RCB 
collected across different countries and clinical settings 
highlights the generalisability of implementing the RCB 
methodology. RCB score has the potential to be used in a 
subtype-specific context to predict a patient’s residual risk after 
neoadjuvant chemotherapy in a prospective setting with 
standardised evaluation of post-treatment resection 
specimens, especially given the increasing options for adjuvant 
therapy in the setting of residual disease.
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with site investigators. For inclusion in this pooled 
analysis of participant­level data, trials or cohorts were 
required to include adult patients (aged ≥18 years) with 
primary stage I–III breast cancer (no positive sentinel 
lymph node biopsy, any phenotypic subtype) treated with 
neoadjuvant chemotherapy followed by surgery; and have 
available data for RCB, and follow­up data to evaluate the 
primary endpoint of event­free survival and the secondary 
endpoint of distant relapse­free survival. Data on Eastern 
Cooperative Oncology Group performance status was not 
available in all patients and thus was not collected. 
Investigators from institutions or trials who were known 
to have assessed and reported RCB in a pre­defined cohort 
were invited to participate between October, 2018, and 
April, 2019 (and all accepted); pooled data was finalised in 
November, 2019. Participating investigators representing 
12 groups (four trials and eight clinical cohorts; appendix 
pp 2–3) from Europe and the USA provided individual 
patient data. We provide references or registration 
numbers for trials and cohorts when available.
The following trials were included: the I­SPY 1 trial,17 
the I­SPY 2 trial,18,20 the ARTemis trial,16 and a trial led by 
the Instituto de Investigación Sanitaria Gregorio 
Marañón (IISGM; Madrid, Spain).19 Two of the trials 
included investigational therapies: the ARTemis study, in 
which bevacizumab was the investigational drug; and 
I­SPY 2, in which nine investigational drugs were 
adaptively randomised (4:1) against a concurrent 
control.18,20 I­SPY 1 and the IISGM trials were both 
observational, evaluating standard chemotherapies 
without any experimental arms.
The eight clinical cohorts were the MDACC cohort 
(MDACC­LAB98­240 and MDACC­LAB02­010 protocols) 
of the MD Anderson Cancer Center (Houston, TX, USA),12 
the NEOREP cohort (CNIL declaration number 157270) 
from the Curie Institute (Paris, France),15 the triple­negative 
breast cancer PROGECT registry of the University of 
Kansas Medical Center (KUMC; Kansas City, KS, USA),13 
the TransNEO cohort from the University of Cambridge 
(Cambridge, UK; European Genome­Phenome number 
EGAS00001004582), and cohorts from the Edinburgh 
Breast Unit at Western General Hospital (Edinburgh, UK; 
Edinburgh Cancer Information Programme Board 
reference number CIR21166), the Mayo Clinic (Rochester, 
MN, USA), the Netherlands Cancer Institute (Amsterdam, 
Netherlands),14 and Yale University (New Haven, CT, USA).
After neoadjuvant treatment and surgery, patients in 
each trial or cohort received adjuvant endocrine therapy, 
HER2 therapy, and locoregional radiotherapy, per their 
institution’s standard of care. For the remainder of this 
Article, we refer to all these trials and clinical cohorts as 
cohorts. Details on the cohorts, including eligibility 
criteria, type of consent, ethical approval, enrolment 
period, and patient characteristics, are provided in the 
appendix (pp 2–3). All patient identifiers were removed 
from data before the data were transferred and collated 
into a single dataset for the present analysis.
Procedures
RCB was assessed by breast cancer pathologists at the 
treating centres (including DdC, ML, JeW, EP, JST, LM, 
AG, FF, KC, and WFS) trained in using the standard 
methods to evaluate and calculate RCB score and class.9 
RCB was evaluated prospectively for five of the 12 cohorts 
(KUMC, I­SPY 2, IISGM, Mayo Clinic, and Yale cohorts), 
whereas RCB was determined in a retrospective review 
by the original investigators for the other seven cohorts 
(appendix pp 2–3). RCB values used in this analysis were 
based on reporting at the treating centre and were not 
centrally reviewed.
RCB (or RCB score) is calculated as a continuous 
variable. To aid in interpretation, cutpoints are applied to 
define four RCB classes indicating progressively larger 
residual disease burden: RCB­0 (RCB score 0, equivalent 
to pCR), RCB­1 (RCB score ≥0–1·36), RCB­2 (RCB 
score 1·37–3·28), and RCB­3 (RCB score >3·28).9
Evaluation of pretreatment histological grade was done 
at the treating institutions according to the Elston–Ellis 
modification of the Scarff–Bloom–Richardson grading 
system.21 Oestrogen receptor (encoded by ESR1) and 
progesterone receptor (encoded by PGR) status used in 
this analysis were as defined and provided by the 
institutions. Two cohorts (ARTemis and TransNEO) only 
recorded oestrogen receptor status and not progesterone 
receptor status. Thus, for our analysis, hormone receptor 
status was determined based on oestrogen and 
progesterone receptor status if both were available; or 
oestrogen receptor status alone if progesterone receptor 
status was not available. In the ARTemis trial, the 
TransNEO cohort, and Edinburgh cohort, hormone 
receptor status was defined as positive if the Allred score 
was 3 or higher. In other cohorts, hormone receptor 
status was defined by the percentage of cells that stained 
positive on immunohistochemistry at either a 1% or 10% 
threshold, depending on the institution. HER2 (ERBB2) 
status was determined according to international guide­
lines at all institutions.22 Hormone receptor and HER2 
status were used to define four phenotypic subtypes 
(hormone receptor­negative, HER2­negative; hormone 
receptor­negative, HER2­positive; hormone receptor­
positive, HER2­positive; and hormone receptor­positive, 
HER2­negative) for analysis. Treatment information, 
such as neoadjuvant HER2­targeted therapy use for 
HER2­positive patients, and histological­type data were 
also collected from the cohorts. Data collected in each 
cohort for the purposes of this study are summarised in 
the appendix (pp 2–3).
Outcomes
The primary endpoint was event­free survival, adapted 
from the standardised definitions proposed in the 
CTNeoBC study, and measured as time from start of 
neoadjuvant treatment to the occurrence of an event.4 
Any locoregional recurrence, distant recurrence, or death 
from any cause was considered as an event­free survival 
See Online for appendix
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event, and patients without an event were censored at the 
date of last follow­up. The secondary endpoint was 
distant relapse­free survival, defined as time from start of 
neoadjuvant therapy to distant recurrence or death from 
any cause. Patients without an event were censored at the 
date of last follow­up. Follow­up was calculated from the 
start date of neoadjuvant chemotherapy.
Statistical analysis
Baseline characteristics are presented as number and 
proportion for categorical variables and median (IQR) for 
continuous variables. IQR bounds were calculated with 
the formula: Q1–(1·5×IQR) and Q3+(1·5×IQR). Both the 
primary and secondary outcomes were assessed in all 
patients in the pooled analysis cohort. The association 
between RCB score and event­free survival and distant 
relapse­free survival in the pooled population was 
assessed with mixed­effects Cox models, which included 
random cohort and RCB effects to account for between­
cohort heterogeneity, and stratification to account for 
differences in baseline hazard across biological breast 
cancer subtypes. The significance of the association was 
determined by the significance of the mean hazard 
ratio (HR) associated with a 1­unit increase in RCB score 
on a log­transformed scale, with a p value lower than 0·05 
as the significance threshold. Similar mixed­effects 
models were used in prespecified subgroup analyses to 
assess the associations between RCB score and event­free 
survival within each breast cancer subtype. In addition, 
multivariable mixed­effects Cox analysis incorporating 
random cohort and RCB effects and adjusting for age, 
pretreatment T category (T0–1, T3, or T4 vs T2), 
pretreatment nodal status (positive vs negative), and 
pretreatment tumour grade (3 vs 1–2; all as fixed effects) 
as covariates were done (overall and within each subtype) 
to evaluate whether or not RCB remains significantly 
prognostic independent of these clinical covariates. We 
also evaluated associations within each participating 
cohort using fixed­effects univariable Cox models 
stratified by subtype. For the two HER2­positive subtypes, 
post­hoc analyses of patient subsets who received 
neoadjuvant HER2­targeted therapies in addition to 
neoadjuvant chemotherapy, which is now standard of 
care, was also performed. Results of the HER2­targeted 
subset are preferentially presented over results for the 
entire set of HER2­positive subtypes due to clinical 
relevance. In addition, to evaluate the non­linear effect of 
RCB on survival, we used B­splines with two degrees of 
freedom in our mixed­effects models and constructed 
relative event rate plots (with an RCB score of 0 as the 
reference) as a function of increasing RCB. Mixed­effects 
analysis was conducted with the coxme package in R 
(version 3.4.3). Kaplan­Meier plots of event­free survival 
and distant relapse­free survival by RCB class, overall 
and within breast cancer subtypes, were constructed with 
survival times truncated at 12 years (a time at which 
around 10% of the smallest patient group [RCB­1] 
remained at risk for an event); survival estimates at 3, 5, 
and 10 years were computed.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
5295 patients from 12 participating groups treated with 
neoadjuvant chemotherapy between Sept 12, 1994, and Feb 
11, 2019 were identified for the pooled analysis. Patients 
with missing RCB score (n=56), a positive sentinel lymph 
node biopsy before neoadjuvant chemotherapy (n=53), 
unknown receptor subtype (n=17), or missing follow­up 
information (n=8) were excluded, yielding a total of 
5161 eligible patients for analysis (figure 1).
Baseline patient and tumour characteristics, RCB class 
distribution, and follow­up information are summarised 
in table 1 for the overall population and by breast cancer 
subtype. In the overall population, median age was 
49 years (IQR 20–80). 1774 (34·4%) of 5161 patients had 
hormone receptor­negative, HER2­negative tumours, 
1430 (27·7%) had HER2­positive tumours (of whom 858 
[60·0%] were hormone receptor­positive and 572 [40·0%] 
hormone receptor­negative) and 1957 (37·9%) had 
hormone receptor­positive, HER2­negative tumours. 
1244 (87·0%) of the 1430 HER2­positive patients received 
5295 patients considered for pooled analysis
 1973 from four neoadjuvant chemotherapy trials
 3322 from eight neoadjuvant chemotherapy cohorts
56 with unknown RCB score
53 with a positive sentinel lymph node biopsy
  before neoadjuvant chemotherapy
5239 patients with RCB score
17 with unknown receptor subtype
5186 patients with RCB score and local disease (stage I–III)
8 missing follow-up data
5169 patients with RCB score, and local disease (stage I–III) and known
 receptor subtype
5161 patients included in pooled analysis
Figure 1: Study profile
RCB=residual cancer burden.
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neoadjuvant HER2­targeted therapy in addition to 
neoadjuvant chemotherapy. Overall, the proportions of 
patients in each RCB class were: 1676 (32·5%) of 5161 in 
RCB­0 (pCR), 662 (12·8%) in RCB­1, 2017 (39·1%) in 
RCB­2, and 806 (15·6%) in RCB­3 (table 1). Median 
follow­up was 56 months (IQR 0–186), with 1164 event­free 
survival events and 1072 distant relapse­free survival 
events.
In the overall population, increased RCB score was 
significantly associated with worse event­free survival 
and distant relapse­free survival overall in univariable 
analysis, with a HR per unit increase in RCB score of 
1·82 (95% CI 1·73–1·91, p<0·0001) for event­free survival 
and 1·86 (1·76–1·97, p<0·0001) for distant relapse­free 
survival (appendix p 4). The log relative hazard rate 
(compared to RCB­0) for event­free survival and distant 
relapse­free survival events became larger with increasing 
RCB score, with a near­linear relationship for the pooled 
population (figure 2A, 2B). Similar associations with 
event­free survival and distant relapse­free survival were 
observed within each participating cohort (appendix p 9).
In multivariable analysis, associations between RCB 
and both event­free survival and distant relapse­free 
survival in the overall population remained significant 
when we adjusted for age, clinical tumour and nodal 
stage categories, and histological grade at baseline (event­
free survival HR 1·69 [1·55–1·85], p<0·0001; distant 
relapse­free survival HR 1·75 [1·60–1·90], p<0·0001). 
Additionally, clinical T3 and T4 category and histological 
grade 3 were associated with significantly increased risk 
of event­free survival and distant relapse­free survival 
events, and node positivity was significantly associated 
with event­free survival events, in the multivariable 
model (table 2, appendix pp 7–8). RCB class was 
prognostic for both event­free survival (figure 2C) and 

































Age, years 49 (20–80) 49 (17–81) 51 (22–78) 51 (22–78) 48 (16–80) 48 (16–80) 49 (20–80)
T category
0–1 466 (9·0%) 174 (9·8%) 56 (9·8%) 45 (9·2%) 84 (9·8%) 76 (10·1%) 152 (7·8%)
2 3139 (60·8%) 1132 (63·8%) 318 (55·6%) 277 (56·8%) 494 (57·6%) 444 (58·7%) 1195 (61·1%)
3 1026 (19·9%) 310 (17·5%) 138 (24·1%) 109 (22·3%) 172 (20·0%) 139 (18·4%) 406 (20·7%)
4 345 (6·7%) 106 (6·0%) 46 (8·0%) 43 (8·8%) 69 (8·0%) 59 (7·8%) 124 (6·3%)
Missing 185 (3·6%) 52 (2·9%) 14 (2·4%) 14 (2·9%) 39 (4·5%) 38 (5·0%) 80 (4·1%)
Node positivity 2780 (53·9%) 806 (45·4%) 360 (62·9%) 298 (61·1%) 499 (58·2%) 429 (56·7%) 1115 (57%)
Histological grade
1 130 (2·5%) 16 (0·9%) 3 (0·5%) 3 (0·6%) 8 (0·9%) 6 (0·8%) 103 (5·3%)
2 1668 (32·7%) 270 (15·2%) 151 (26·4%) 130 (26·6%) 356 (41·5%) 313 (41·4%) 911 (46·6%)
3 2945 (57·1%) 1348 (76·0%) 378 (66·1%) 317 (65·0%) 437 (50·9%) 381 (50·4%) 782 (40%)
Missing 398 (8·1%) 140 (7·9%) 40 (7%) 38 (7·8%) 57 (6·6%) 56 (7·4%) 161 (8·2%)
Histological type
Ductal or mixed ductal 4790 (92·8%) 1690 (95·3%) 542 (94·8%) 461 (94·5%) 814 (94·9%) 719 (95·1%) 1744 (89·1%)
Lobular 216 (4·2%) 19 (1·1%) 10 (1·7%) 9 (1·8%) 28 (3·3%) 24 (3·2%) 159 (8·1%)
Other 100 (1·9%) 42 (2·4%) 16 (2·8%) 14 (2·9%) 13 (1·5%) 10 (1·3%) 29 (1·5%)
Unknown or missing 55 (1·1%) 23 (1·3%) 4 (0·7%) 4 (0·8%) 3 (0·3%) 3 (0·4%) 25 (1·3%)
Postneoadjuvant chemotherapy: RCB class
RCB-0 1676 (32·5%) 770 (43·4%) 376 (65·7%) 336 (68·9%) 313 (36·5%) 290 (38·4%) 217 (11·1%)
RCB-1 662 (12·8%) 212 (12·0%) 67 (11·7%) 55 (11·3%) 172 (20·1%) 153 (20·2%) 211 (10·8%)
RCB-2 2017 (39·1%) 590 (33·3%) 100 (17·5%) 76 (15·6%) 291 (33·9%) 250 (33·1%) 1036 (52·9%)
RCB-3 806 (15·6%) 202 (11·4%) 29 (5·1%) 21 (4·3%) 82 (9·6%) 63 (8·3%) 493 (25·2%)
Follow-up information
Follow-up, months 56 (0–186) 45 (0–140) 69 (0–219) 65 (0–193) 64 (0–197) 61 (0–176) 58 (0–200)
Event-free survival events 1164 450 95 62 154 118 465
Distant relapse-free 
survival events
1072 417 79 53 135 100 441
Data are n, n (%), or median (IQR). Negative values for the lower IQR bound are truncated at 0. RCB=residual cancer burden. *The subset who received neoadjuvant HER2-targeted therapy as neoadjuvant 
treatment in combination with chemotherapy.
Table 1: Patient characteristics overall and by breast cancer subtype
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population, with clear prognostic separation between 
each class.
Event­free survival estimates for patients within the 
RCB­0 class were 94% (95% CI 93–95) at 3 years, 
91% (90–93) at 5 years, and 88% (85–90) at 10 years; 
compared with 91% (89–93), 86% (84–89), and 
80% (76–84) for RCB­1; 82% (81–84), 74% (72–76), and 
65% (62–68) for RCB­2; and 66% (63–70), 58% (54–62), 
and 45% (40–49) for RCB­3 (figure 2C, appendix pp 4–6). 
Similarly, distant relapse­free survival estimates were 
95% (95% CI 94–96), 93% (91–94), and 90% (88–92) for 
RCB­0 at 3, 5, and 10 years; compared with 92% (90–94), 
89% (86–91), and 81% (77–85) for RCB­1; 84% (83–86), 
77% (75–79), and 67% (65–70) for RCB­2; and 68% (65–71), 
60% (56–63), and 46% (41–51) for RCB­3 (figure 2D, 
appendix pp 4–6).
Figure 2: Prognostic value of RCB score and RCB class in the overall pooled analysis cohort
Plots of log relative hazard rate for event-free survival events (A) and distant relapse-free survival events (B) as a function of RCB score. Splines approximation of RCB with two degrees of freedom was 
used to allow for non-linear effect. A log linear increase in relative hazard rate implies that the hazard ratio associated with change in RCB remains constant over the range of RCB. Thresholds for 
corresponding RCB classes (RCB-0 to RCB-3) are shown for reference (vertical dashed lines). Vertical bars represent all RCB scores recorded on a continuous scale. Kaplan-Meier plots of event-free 
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Increased RCB score was significantly associated with 
worse event­free survival within all four breast cancer 
subtypes, with the HR associated with one unit increase 
in RCB score ranging from 1·55 (1·41–1·71) in the 
hormone receptor­positive, HER2­negative group to 
2·16 (1·79–2·61) in the hormone receptor­negative, 
HER2­positive group (p<0·0001 for all subtypes; 
appendix pp 4–6). Similar findings were observed when 
considering only patients with hormone receptor­
negative, HER2­positive tumours (488 of 572) or hormone 
receptor­positive, HER2­positive tumours (756 of 858) 
who received neoadjuvant HER2­targeted therapies with 
neoadjuvant chemotherapy (appendix pp 5–6). Increasing 
RCB was associated with a near­linear increase in log 
relative hazard rate among all breast cancer subtypes, 
except for the hormone receptor­positive, HER2­negative 
subtype, in which the log relative hazard rate remained 
near zero until an RCB score of around 1·5, close to the 
class threshold between RCB­1 and RCB­2 (figure 3; 
appendix p 11). The results were similar for distant 
relapse­free survival (appendix pp 4–6, 10–11).
In the multivariable analysis, RCB score remained a 
significant independent predictor of event­free survival 
and distant relapse­free survival in all breast cancer 
subtypes when we adjusted for baseline characteristics 
(table 2, appendix pp 7–8). For event­free survival, the 
adjusted HR associated with a one­unit increase in RCB 
score ranged from 1·52 (95% CI 1·36–1·69) in the 
hormone receptor­positive, HER2­negative group to 2·09 
(1·73–2·53) in the hormone receptor­negative, HER2­
positive group (p<0·0001 for all subtypes; appendix p 7). 
Similar results were observed for the distant relapse­free 
survival endpoint (appendix p 8).
Despite differences in the distribution of RCB class 
between different breast cancer subtypes, we observed 
clear prognostic separation for event­free survival 
between patients with RCB­2 or RCB­3 disease and those 
who achieved a pCR (RCB­0) in all subtypes (figure 4, 
appendix pp 4–6, 13). Within the hormone receptor­
negative, HER2­negative and hormone receptor­positive, 
HER2­positive subtypes, significant differences were 
also observed between the RCB­1 and RCB­0 groups 
(appendix pp 4–6). Notably, in the hormone receptor­
positive, HER2­positive group who received HER2­
targeted therapy, patients within the RCB­0 and RCB­1 
classes showed similar event­free survival in the first 
5 years (5­year event­free survival 94% [95% CI 91–97] 
and 91% [85–96], respectively) before their prognosis 
diverged; at 10 years, the event­free survival of RCB­0 
patients was 91% (95% CI 86–97), compared with 
83% (75–92) for RCB­1 patients (post­hoc analysis; 
figure 4C). Within the hormone receptor­positive, HER2­
negative subtype, consistent with the non­linear 
relationship between event­free survival and continuous 
RCB, RCB­0 and RCB­1 patients had similar event­free 
survival (HR 0·97 [0·57–1·65], p=0·90; figure 4D, 
appendix pp 4–6). The characteristics of event­free 
survival events among hormone receptor­positive, 
HER2­negative RCB­0 patients are shown in the 
appendix (p 14). Results for the distant relapse­free 
survival endpoint were similar to those for event­free 
survival (appendix pp 4–6, 12).
Discussion
In this pooled analysis, we showed that RCB is prognostic 
across 12 independent cohorts of patients, irrespective of 
pretreatment clinicopathological features and regardless 
of hormone receptor and HER2 subtype. At present, no 
universally adopted standard methodological approach is 

































RCB 1·69 (1·55–1·85)‡ 1·93 (1·74–2·13)‡ 2·09 (1·73–2·53)‡ 2·10 (1·68–2·62)‡ 1·66 (1·45–1·90)‡ 1·69 (1·45–1·97)‡ 1·52 (1·36–1·69)‡
Age 1·00 (0·99–1·00) 0·99 (0·98–1·00)‡ 1·00 (0·98–1·02) 1·00 (0·97–1·03) 1·00 (0·99–1·02) 1·00 (0·98–1·02) 1·00 (0·99–1·01)
T category (reference: T2)§
T0–1 1·08 (0·85–1·37) 1·05 (0·69–1·60) 1·99 (1·00–3·96) 2·46 (1·03–5·87)‡ 0·80 (0·40–1·61) 0·50 (0·20–1·26) 1·01 (0·69–1·46)
T3 1·28 (1·10–1·49)‡ 1·73 (1·37–2·18)‡ 1·60 (0·95–2·69) 1·64 (0·83–3·24) 1·02 (0·66–1·56) 0·88 (0·53–1·48) 1·08 (0·85–1·37)
T4 1·89 (1·55–2·31)‡ 1·43 (1·02–2·01)‡ 1·27 (0·60–2·68) 2·39 (1·02–5·58)‡ 3·23 (2·07–5·03)‡ 2·98 (1·81–4·90)‡ 2·11 (1·53–2·91)‡
Nodal status (reference: node negativity)
Node positivity 1·15 (1·00–1·32)‡ 1·17 (0·94–1·44) 0·87 (0·52–1·45) 0·72 (0·38–1·35) 1·25 (0·84–1·86) 1·34 (0·85–2·11) 1·30 (1·04–1·62)‡
Grade (reference: grade 1–2)
Grade 3 1·51 (1·33–1·72)‡ 1·09 (0·85–1·40) 0·96 (0·58–1·59) 0·86 (0·46–1·63) 0·76 (0·55–1·06) 0·68 (0·46–0·99)‡ 1·55 (1·27–1·89)‡
RCB was analysed as a continuous score, adjusting for age and pretreatment T category, nodal status, and grade (as fixed effects). Hazard ratios (95% CIs) are shown. All p values are shown in the appendix (p 7). 
RCB=residual cancer burden. *Patients with complete covariate data. †The subset who received neoadjuvant HER2-targeted therapy as neoadjuvant treatment in combination with chemotherapy. ‡Indicates 
significant p values less than 0·05. §T2 was used as the reference category due to the small sample size of the T0–1 group (particularly within the HER2-positive subtypes) in view of concern for the stability of the 
hazard ratio estimates.
Table 2: Multivariable mixed-effects Cox models of event-free survival as a function of RCB
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Figure 3: Prognostic value of RCB score within hormone receptor and HER2 subtypes
Plots of log relative hazard rate for event-free survival events as a function of RCB score among breast cancer subtypes. For the two HER2-positive subtypes, 
plots of the subset of patients who received neoadjuvant HER2-targeted therapy are shown (plots for all HER2-positive patients, with or without HER2-targeted 
therapy, are presented in the appendix p 11). Splines approximation of RCB with two degrees of freedom was used to allow non-linear effect. A log linear 
increase in relative hazard rate implies that the hazard ratio associated with change in RCB remains constant over the range of RCB. Thresholds for corresponding 
RCB classes (RCB-0 to RCB-3) are shown for reference (vertical dashed lines). Vertical bars represent all RCB scores recorded on a continuous scale. RCB=residual 
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neoadjuvant chemotherapy in breast cancer.23 More than 
10 years ago, the degree of residual invasive disease in 
breast cancer was not believed to be of crucial importance 
for patient management, in part because mastectomy 
was the gold standard for patients with locally advanced 
breast cancer. Use of neoadjuvant chemotherapy 
increased as improved systemic therapies emerged and 
research evidence showed that breast conservation 
following neoadjuvant chemotherapy led to similar 
outcomes to mastectomy.24 Several studies have since 
shown the strong prognostic relationship between the 
presence or extent of residual disease and the risk of 
Figure 4: Prognostic value of RCB class for hormone receptor and HER2 subtypes
Kaplan-Meier plots of event-free survival by RCB classes among breast cancer subtypes. For the two HER2-positive subtypes, plots of the subset of patients who received neoadjuvant HER2-targeted 
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locoregional and distant recurrences.9,10,17 In this analysis, 
the number of event­free survival and distant relapse­free 
survival events was similar (1164 vs 1072), indicating that 
distant recurrences are the predominant risk for patients 
selected for neoadjuvant chemotherapy. Our definitions 
of event­free survival and distant relapse­free survival 
endpoints are consistent with the CTNeoBC meta­
analysis4 and the standardised definitions for efficacy 
endpoints system (commonly known as STEEP), which 
recommends the date of first therapy as the starting 
point for time­to­event calculations.
Important aspects to the RCB method are that it 
provides both a standardised approach for pathological 
evaluation of post­treatment resection specimens and an 
algorithm that quantifies the extent of residual disease. 
Studies have reported highly reproducible measurements 
of RCB from different pathologists10,11 and the prognostic 
value of RCB has been validated in several single­centre 
studies and multicentre trials.12–19 Indeed, in this pooled 
analysis, we observed significant associations between 
RCB and event­free survival or distant metastasis­free 
survival in the overall population, within all breast cancer 
subtypes, and across all cohorts (except in the smallest 
cohort for event­free survival). Since our pooled cohorts 
represent a variety of clinical settings, this result implies 
a broad generalisability of the association between RCB 
and prognosis in the overall patient population and 
within each molecular subtype of breast cancer.
Importantly, the risk of a recurrence event increased 
with the extent of residual disease, regardless of breast 
cancer subtype. Use of RCB, therefore, adds prognostic 
information when pCR is not achieved. As more 
post­neoadjuvant (adjuvant) therapy options become 
available for patients with residual disease, a refined 
estimate of an individual’s risk of recurrence, based on 
their subtype and RCB, might be useful for informing 
decisions on adjuvant treatment selection. Interestingly, 
unlike in the hormone receptor­negative and hormone 
receptor­positive, HER2­positive subtypes, the increase 
in risk with RCB seems to be non­linear in the hormone 
receptor­positive, HER2­negative subtype. One potential 
reason for this relationship might be that the outcomes 
of some patients with hormone receptor­positive, HER2­
negative cancer might not be dependent on response to 
neoadjuvant chemotherapy, but depend on the effects of 
the endocrine therapy that they usually receive for 5 years 
or longer.25 This result highlights the importance of 
subtypes in prognostication and suggests that use of 
RCB for recurrence risk prediction after neoadjuvant 
therapy should be performed within a subtype­specific 
context.
The weakest association between RCB and survival was 
in patients with hormone receptor­positive, HER2­negative 
tumours, among whom the RCB­0 and RCB­1 groups had 
similar event­free survival. This similarity in survival 
appeared to be driven by a few early recurrence events in 
the RCB­0 group (16 within the first 3 years). Five of these 
early recurrences occurred in the bevacizumab group of 
the ARTemis trial and might be attributable to a differential 
effect of bevacizumab, which increases pCR rates in the 
primary tumour but has less effect on micrometastatic 
disease.26 Variation in how hormone receptor positivity was 
defined across sites might also have an important role in 
the higher than expected early recurrence rates in the 
hormone receptor­positive, HER2­negative RCB­0 group. 
Three groups used Allred score, three groups defined 
positivity as more than 1% of cells with oestrogen receptor­
positive staining, and others defined it as more than 10%, 
reflecting uncertainty on how to classify hormone receptor­
low tumours. Five of the early recurrences in the hormone 
receptor­positive, HER2­negative RCB­0 group were 
observed in oestrogen receptor­negative (progesterone 
receptor­low) or oestrogen receptor­low (progesterone 
receptor­negative) cases. Whether these hormone receptor­
low cases were more similar to hormone receptor­negative 
tumours or to their strongly hormone receptor­positive 
counter parts remains an unanswered question. Character­
isation with various molecular subtypes, previously shown 
to associate with responsiveness to therapy and prognosis, 
might be informative.27
This study has several additional limitations. Patients 
received a range of neoadjuvant therapies (chemotherapy 
was given per each cohort institution’s standard of care 
with or without additional targeted therapies) and we did 
not control for treatment type or duration of treatment in 
this analysis. However, a previous analysis of the I­SPY 2 
trial (cohort 2 in our analysis, appendix pp 2–3) suggests 
that the prognostic association of both pCR and RCB 
score is strong, regardless of type of chemotherapy­based 
treatment.18,20 Additionally, not all participating groups 
performed extensive metastatic workup as part of 
standard clinical care before neoadjuvant therapy, and 
the length of follow­up differed among the included 
cohorts. Furthermore, the proportion of lobular cancers 
in our study was less than the proportion of lobular cases 
in the overall breast cancer population,28,29 possibly 
reflecting the common belief among clinicians that 
lobular cancers do not respond well to neoadjuvant 
chemotherapy, and therefore clinicians do not select 
patients with lobular cancers for neoadjuvant therapy.
In this analysis, seven of 12 groups calculated RCB 
retrospectively, some reviewing specimens only when 
RCB or its components were unavailable in the original 
pathology report or only when residual disease was 
reported. pCR rate can decrease when the RCB method 
is incorporated into practice, possibly because a 
standardised and more focused pathological evaluation 
of the original tumour bed can identify residual disease 
that might otherwise have been missed.30 This is a 
shortcoming of retrospective pathology review because 
inaccurate sampling of the surgical specimen is the 
greatest potential source of residual disease misdiagnosed 
as pCR, and sampling accuracy cannot be determined by 
reviewing the slides. This limitation is particularly 
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relevant in the hormone receptor­positive, HER2­
negative subtype in which the proportion of diffuse 
disease is greater than in other subtypes,31 increasing the 
likelihood that sampling could affect the classification of 
RCB­0 and RCB­1. Additionally, only the most recent 
cohorts in our analysis used clips as standard practice to 
mark the sites, assuring that the original tumour bed was 
sampled. Prospective assessment of RCB, along with 
careful identification of the initial site of disease, might 
improve the overall prognostic performance of RCB. 
This approach should particularly apply in the setting of 
mastectomy, because it allows pathologists to identify the 
original site of disease using specimen radiographs and 
the clip placed during the biopsy at diagnosis for careful 
characterisation of the tumour bed.
Despite these limitations, the consistency of the 
prognostic importance of RCB across participating 
groups in our study highlights the generalisability of 
implementing and standardising the entire RCB 
methodology, from the stage of tissue acquisition to the 
final pathology assessment, across different countries, 
neoadjuvant chemotherapy treatments, and clinical 
settings. Altogether, our findings suggest that the RCB 
score has potential to be calibrated in a subtype­specific 
context to predict a patient’s residual risk after 
neoadjuvant chemotherapy in a prospective setting with 
standardised evaluation of post­treatment resection 
specimens. Given the increasing options for escalation 
and de­escalation of adjuvant therapy in the setting of 
residual disease, prospective evaluation of RCB as part of 
standard pathology reporting following neoadjuvant 
therapy might be warranted.
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